Page last updated: 2024-12-05

adrenochrome

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Adrenochrome: Pigment obtained by the oxidation of epinephrine. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5898
CHEMBL ID1314174
CHEBI ID166544
SCHEMBL ID61927
MeSH IDM0000498

Synonyms (40)

Synonym
54-06-8
3-hydroxy-1-methyl-2,3-dihydroindole-5,6-dione
CHEBI:166544
adraxone
5,6-indolinedione, 3-hydroxy-1-methyl-
1h-indole-5,6-dione, 2,3-dihydro-3-hydroxy-1-methyl-
usaf uctl-7
3-hydroxy-1-methylindoline-5,6-dione
einecs 200-192-8
3-hydroxy-1-methyl-5,6-indolinedione
2,3-dihydro-3-hydroxy-1-methyl-1h-indole-5,6-dione
nsc383491
adrenochrome
nsc-383491
adrenochrome, l-
NSC407840 ,
1-adrenochrome
7506-92-5
nsc-407840
NCGC00163348-01
adrenochrome, free base
A-3200
AKOS006229902
unii-70g54nql71
70g54nql71 ,
FT-0621930
adrenochrome [mi]
SCHEMBL61927
CHEMBL1314174
3-hydroxy-1-methyl-2,3,5,6-tetrahydro-1h-indole-5,6-dione
adrenochrom
adrenochrome free base
3-hydroxy-1-methyl-2,3-dihydro-1h-indole-5,6-dione
Q366835
d,l-adrenochrome
DTXSID00871530
d,l-adrenochrome; 3-hydroxy-1-methyl-5,6-indolinedione; 2,3-dihydro-3-hydroxy-1-methyl-1h-indole-5,6-dione pound>>phenylephrine impurity 1 pound>>adraxone
BCP30577
HY-116513
CS-0065676

Research Excerpts

Overview

Summarize : Adrenochrome is an oxidative product of adrenaline and possesses cardiotoxic properties.

ExcerptReferenceRelevance
"Adrenochrome is an oxidative product of adrenaline and possesses cardiotoxic properties. "( Studies on the role of superoxide anion radicals for the cardiotoxicity of adrenochrome.
Güttler, K; Klaus, W; Rösen, R; Rump, AF; Schierholz, J, 2001
)
1.98

Effects

ExcerptReferenceRelevance
"Adrenochrome has been shown to produce cardiac necrosis as well as failure in the isolated rat hearts. "( Modification of adrenochrome-induced cardiac contractile failure and cell damage by changes in cation concentrations.
Beamish, RE; Dhalla, NS; Singal, PK; Taam, GM; Yates, JC, 1980
)
2.05

Treatment

ExcerptReferenceRelevance
"Adrenochrome-treatment (10(-6) M or 10(-4) M) was started after a reperfusion period of 20 min."( Cardiotoxicity of adrenochrome in isolated rabbit hearts assessed by epicardial NADH fluorescence.
Klaus, W; Rump, AF, 1994
)
1.34

Toxicity

ExcerptReferenceRelevance
" In the second part of the toxicity of aminochromes, mainly at the cardiac and CNS level, is described and some of the molecular mechanisms of the toxic action are outlined."( Toxicity of aminochromes.
Bindoli, A; Galzigna, L; Rigobello, MP, 1989
)
0.28

Pharmacokinetics

ExcerptReferenceRelevance
"A highly selective and sensitive liquid chromatography coupled with atmospheric pressure chemical ionization tandem mass spectrometry (LC-APCI-MS-MS) was developed and validated for the quantitation and pharmacokinetic study of carbazochrome sodium sulfonate in human plasma."( Development and validation of a robust LC-MS-MS with atmospheric pressure chemical ionization for quantitation of carbazochrome sodium sulfonate in human plasma: application to a pharmacokinetic study.
Hang, T; Song, M; Wang, L; Wen, A; Yang, L; Zhao, H, 2010
)
0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
" In a clinical study, 65 patients with lung cancer were treated with more than 50 Gy of RT with or without combination with AMM+CCC, OK-432 or AMM+CCC+OK-432."( Differential action on cancer and normal tissue by adrenochrome monoaminoguanidine methanesulfonate and cytochrome C combined with radiotherapy.
Nakatsugawa, S; Sugahara, T, 1994
)
0.54
"The hemostatic effect of tranexamic acid (TXA) combined with carbazochrome sodium sulfonate (CSS) in total hip arthroplasty (THA) has not been determined."( Effects of carbazochrome sodium sulfonate combined with tranexamic acid on hemostasis and inflammation during perioperative period of total hip arthroplasty: A randomized controlled trial.
Kang, P; Liu, Z; Luo, Y; Releken, Y; Yang, D; Yue, Y, 2022
)
0.72
"CSS combined with TXA can effectively reduce perioperative blood loss and immune response compared to TXA."( Effects of carbazochrome sodium sulfonate combined with tranexamic acid on hemostasis and inflammation during perioperative period of total hip arthroplasty: A randomized controlled trial.
Kang, P; Liu, Z; Luo, Y; Releken, Y; Yang, D; Yue, Y, 2022
)
0.72
" In addition, CSS combined with TXA is better than TXA alone in terms of improving postoperative hip pain and reducing the level of inflammatory factors."( Effects of carbazochrome sodium sulfonate combined with tranexamic acid on hemostasis and inflammation during perioperative period of total hip arthroplasty: A randomized controlled trial.
Kang, P; Liu, Z; Luo, Y; Releken, Y; Yang, D; Yue, Y, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" The dosage was for Divascan 15 mg a day and for pizotifen 3 mg a day."( A comparison between placebo, pizotifen and 1-isopropyl-3-hydroxy-5-semicarbazono-6-oxo-2.3.5.6-tetrahydroindol (Divascan) in migraine prophylaxis.
Osterman, PO, 1977
)
0.26
"Four simple, accurate, sensitive and precise spectrophotometric methods were developed and validated for simultaneous determination of Troxerutin (TXN) and Carbazochrome (CZM) in their bulk powders, laboratory prepared mixtures and pharmaceutical dosage forms."( Validated spectrophotometric methods for simultaneous determination of troxerutin and carbazochrome in dosage form.
Al-Ghobashy, MA; Ghoniem, NS; Hegazy, MA; Khattab, FI; Ramadan, NK, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indolesAny compound containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.39810.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.22390.004023.8416100.0000AID485290
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency2.81840.125919.1169125.8920AID2549
phosphopantetheinyl transferaseBacillus subtilisPotency5.62340.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency18.47820.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency7.87580.180013.557439.8107AID1460; AID1468
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.25890.035520.977089.1251AID504332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency11.22020.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency50.11870.010039.53711,122.0200AID1479
DNA polymerase kappa isoform 1Homo sapiens (human)Potency0.31620.031622.3146100.0000AID588579
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency14.12540.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (574)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990464 (80.84)18.7374
1990's45 (7.84)18.2507
2000's31 (5.40)29.6817
2010's23 (4.01)24.3611
2020's11 (1.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 105.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index105.54 (24.57)
Research Supply Index6.52 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index195.48 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (105.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials36 (5.60%)5.53%
Reviews16 (2.49%)6.00%
Case Studies12 (1.87%)4.05%
Observational1 (0.16%)0.25%
Other578 (89.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]